David,
We had a pretty long discussion about this. Re-read this post also please
http://www.hairlosstalk.com/interac...ipiprant-log?p=1286085&viewfull=1#post1286085.
To give you an exact answer to your question let me explain you this. The research that came out about PGD2 is not new. This is news from already 4 years ago, yes that's right 4 years ago. It's old as hell now;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319975/.
Back then people IMMEDIATELY started to self experiment. It was way bigger back then. Look here at a topic that has over a million views about this from early 2012;
https://goo.gl/ZjCXsJ
So what did people do? They started searching for CRTH2 (DP2) antagonists and found two of them, OC459 and TM30089. They are basically just other molecules than setipiprant, with the same biological activity (selective DP2 antagonists), but more potent. Just like dutasteride has more potency towards 5ar2 than finasteride. And just like CB-03-01 is probably weaker than RU58841 towards the androgen receptor.
So they trialled the stuff with high expectations. Results? "Decreased itch and shedding". A whole army of people tried the stuff and it never got mainstream. After a while only very few continued to use the stuff.
It was mostly one big disappointment. It didn't live up to expectations, outside of the anecdotal results of decreased itch and shedding nobody got any cosmetic improvement whatsoever.
So then it was quiet and this angle only got back to life when Kythera decided to move forward to trial setipiprant for Androgenetic Alopecia. Most (new) people got hyped again and groupbuys were held. Some as high as $340 for 25G of setipiprant, a insane mark-up from the cult forum.
So setipiprant was predictable David. The anecdotal reports about setipiprant now? It's exactly the same as the other molecules! It's overall one big disappointment mate. Again, predictable as hell.
Perhaps you understand me a little bit better now why I don't think that setipiprant won't reach the market. Simply because it won't be effective enough. Like I said I would bet my money linea recta on this. I'm waiting for someone to bet me on this
.
Hitting on the Androgen/AR angle is miles better.
That being said while I'm highly sure that it won't reach the market, it might be an alternative route for someone who can't hit upon the androgen/AR angle. Perhaps doing something instead of doing nothing is better in this case. Up to you to decide man.
Ultimately though indeed David the trials will give us an final answer. But it's not true until proven otherwise. It's a hypothesis after all.